Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ian C. Mortimer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 364
- Beta
- 0.63
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 63.82
Financials
Revenue
$0.00-100.0%Net Income
$-110.74MEBITDA
$-111.32MFree Cash Flow
$-95.67MEPS (diluted)
$-1.11Shares Outstanding (diluted)
99.61M+552.4%Operating Expenses
$123.16MCash & Debt
$930.69MRevenue by Segment (annual)
$9.43MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.50M | $-345.91M | $-4.36 |
| 2024 | $0.00 | $-234.33M | $-3.01 |
| 2023 | $0.00 | $-182.39M | $-2.73 |
| 2022 | $9.43M | $-125.37M | $-2.06 |
| 2021 | $18.44M | $-78.88M | $-1.77 |
| 2020 | $32.17M | $-28.84M | $-0.83 |
| 2019 | $6.83M | $-41.59M | $-1.54 |
| 2018 | $0.00 | $-34.50M | $-1.78 |
| 2017 | $311.0K | $-30.70M | $-1.71 |
| 2016 | $1.80M | $-23.00M | $-1.48 |
| 2015 | $15.58M | $-15.75M | $-1.10 |
| 2014 | $28.37M | $13.02M | $0.94 |
| 2013 | $27.36M | $12.03M | $0.42 |
| 2012 | $14.31M | $-4.30M | $-3.23 |
Valuation
XENEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-33.33%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·1d ago·Negative
Xenon to Present at Wells Fargo Healthcare Conference VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:
View source ↗ - Newsglobenewswire.com·9d ago·Negative
…ta and Rational Polytherapy Potential for Azetukalner at EEC 2026 VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced multiple data presentations at the upcoming 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in Athens, Greece.
View source ↗
Earnings
Mon, Nov 2(in 8 weeks)
Consensus estimate $-1.17 per share
Typical surprise +0.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-1.11 vs $-1.14beat
- Thu, May 7$-1.17 vs $-1.17beat
- Thu, Feb 26$-1.31 vs $-1.20miss
- Mon, Nov 3$-1.15 vs $-1.16beat
- Mon, Aug 11$-1.07 vs $-1.03miss
- Mon, May 12$-0.83 vs $-0.94beat
Estimates and results for XENE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by XENE officers and directors.
- Bought
- —
- Sold
- $23.0m
0 trades
27 trades
- Kenney Christopher Johnsold
- Kenney Christopher Johnsold
- Gannon Stevensold
- Patou Garysold
- Cannon Gilliansold
- Kenney Christopher Johnsold
- Difabio Andreasold
- Mortimer Iansold
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.